Rare actinomycetes: A potential storehouse for novel antibiotics

Critical Reviews in Biotechnology

Volumn 32, Issue 2, 2012, Pages 108-132

  Tiwari, Kavita ^a   Gupta, Rajinder K ^a  

^a GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

Author keywords

Actinomadura; Actinoplanes; Antibiotics; Dactylosporangium; Kibdelosporangium; Microbispora; Micromonospora; Rare actinomycetes; Salinospora; Streptosporangium; Verrucosispora

Indexed keywords

ACTINOMADURA; ACTINOPLANES; DACTYLOSPORANGIUM; KIBDELOSPORANGIUM; MICROBISPORA; MICROMONOSPORA; RARE ACTINOMYCETES; SALINOSPORA; STREPTOSPORANGIUM; VERRUCOSISPORA;

ANTIBIOTICS; MICROBIOLOGY;

BACTERIA;

ANTHRACYCLINE; ANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; ANTIBIOTIC AGENT; ANTIBIOTIC G 418; CALICHEAMICIN; DACTINOMYCIN; DAUNORUBICIN; DIBENZAZEPINE DERIVATIVE; DOXORUBICIN; DYNEMICIN A; EVERNINOMICIN; FORTIMICIN; GENTAMICIN; GLYCOSIDE; K 13; LACTONE; LIPOPEPTIDE; MACROLIDE; MEGALOMICIN; MICROCIN B17; MICRONOMICIN; MYCINAMICIN; NAPHTHOQUINONE; PYRAZINE; RIBONUCLEOSIDE; ROSARAMICIN; SISOMICIN; THIOCORALINE; UNINDEXED DRUG;

ACTINOBACTERIA; CHEMICAL STRUCTURE; DRUG ISOLATION; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STREPTOMYCETACEAE;

ACTINOBACTERIA; ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; HUMANS;

ACTINOBACTERIA; ACTINOBACTERIA (CLASS); ACTINOMADURA; ACTINOPLANES; DACTYLOSPORANGIUM; KIBDELOSPORANGIUM; MICROBISPORA; MICROMONOSPORA; SALINISPORA; STREPTOSPORANGIUM; VERRUCOSISPORA;

EID: 84860644406     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2011.562482     Document Type: Review

References (104)

1. Amann RI, Ludwig W, Schleifer K-H. (1995). Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev, 59, 143-169.
2. Ashton C. (1999). Reinventing drug development. Chem Ind, 11, 422-425.
3. Ausman DJ. (2001). Screening's age of insecurity. Mod Drug Discovery, 4, 32-39.
4. Baltz RH. (2005). Antibiotic discovery from actinomycetes: will a renaissance follow the decline and fall? SIM News, 55, 186-196.
5. Baltz RH. (2006). Combinatorial biosynthesis of novel antibiotics and other secondary metabolites in actinomycetes. SIM News, 56, 148-160.
6. Baltz RH. (2007). Antimicrobials from actinomycetes: back to the future. Microbe, 2, 125-131. (Pubitemid 47619467)
7. Baltz RH. (2008). Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol, 8, 557-563
8. Bardone MR, Paternoster M, Coronelli C. (1978). Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. J Antibiot, 31, 170-177.
9. Beggs M, Long AC. (2002). High throughput genomics and drug discovery parallel universes or a continuum? Drug Discov World, 3, 75-80.
10. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodwardm J, Barrell BG, Parkhill J, Hopwood DA. (2002). Complete genome sequence of the model actinomycetes Streptomyces coelicolor A3(2). Nature, 417, 141-147. (Pubitemid 34506788)
11. Blunt JW, Copp BR, Hu V-P, Munro HG, Northcote PT, Prinsep MR. (2007). Marine natural products. Nat Prod Rep, 24, 31-86. (Pubitemid 46238589)
12. Bostian KA, Schmid MB. (1997). New Antibacterial Targets and New Approaches for Drug Discovery. In: Busse WD, Zeiler HJ, Labischinski H, eds. Antibacterial Therapy: Achievements, Problems and Future Perspectives. Berlin: Springer-Verlag, 61-68.
13. Bredholt H, Fjaervik E, Johnsen G, Zotchev SB. (2008). Actinomycetes from sediments in the Trondheim Fjord, Norway: diversity and biological activity. Mar Drugs, 6, 12-24. (Pubitemid 351543687)
14. Broach JR, Thorner J. (1996). High-throughput screening for drug discovery. Nature, 384S, 14-16. (Pubitemid 26374533)
15. Bulina TI, Alferova IV, Terekhova LP. (1997). A new method for the isolation of actinomycetes with the use of microwave irradiation of soil samples. Mikrobiologiya, 66, 278-282. (Pubitemid 127759184)
16. Bulina TI, Terekhova LP, Tyurin MV. (1998). Use of electric pulses for isolation of actinomycetes from soil. Mikrobiologiya, 67, 556-560. (Pubitemid 128735250)
17. Bull AT, Stach JE. (2007). Marine actinobacteria: new opportunities for natural product search and discovery. Trends Microbiol, 15, 491-499. (Pubitemid 350102189)
18. Bull AT, Goodfellow M, Slater JH. (1992). Biodiversity as a source of innovation in biotechnology. Annu Rev Microbiol, 42, 219-257.
19. Bull AT, Stach JEM, Ward AC, Goodfellow M. (2005). Marine actinobacteria: perspectives, challenges, future directions. Antonie van Leeuwenhoek, 87, 259-276.
20. Butler MS, Buss AD. (2006). Natural products-the future scaffolds for novel antibiotics? Biochem Pharmacol, 71, 919-929.
21. Cai Y, Xue Q, Chen Z, Zhang R. (2009). Classification and salt-tolerance of actinomycetes in the Qinghai Lake water and Lakeside saline soil. J Sustainable Dev, 2, 107-110.
22. Cho SH, Hwang CW, Chung HK, Yang CS. (1994). A new medium for the selective isolation of soil actinomycetes. K J Appl Microbiol Biotechnol, 22, 561-563.
23. Ciabatti R, Cavalleri B. (1989). Ramoplanin (A/16686): a new glycodepsipeptide antibiotic from Actinoplanes. Progr Ind Microbiol, 27, 205-219.
24. Contag PR. (2002). Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov Today, 7, 555-562. (Pubitemid 34603646)
25. Cooper R, Das P, Federbush C, Mierzwa R, Patel M, Pramanik B, Truumees I. (1990). Characterization of peptidyl-nucleoside antifungal antibiotics from fermentation broth. J Ind Microbiol, 5, 1-8. (Pubitemid 20063786)
26. Cutler P, Birrell H, Haran M, Man W, Neville B, Rosier S, Skehel M, White I. (1999). Proteomics in pharmaceutical research and development. Biochem Soc Trans, 27, 555-559. (Pubitemid 29412488)
27. Davies J. (1999). Millennium bugs. Trends Biochem Sci, 24, M2-M5
28. Demain AL. (2002). Prescription for an ailing pharmaceutical industry. Nat Biotechnol, 20, 331-334.
29. Donadio S, Monciardini P, Alduina R, Mazza P, Chiocchini C, Cavaletti L, Sosio M, Puglia A-M. (2002). Microbial technologies for the discovery of novel bioactive metabolites. J Biotechnol, 99, 187-198. (Pubitemid 35223319)
30. Eccleston GP, Brooks PR, Kurtböke DI. (2008). The occurrence of bioactive micromonosporae in aquatic habitats of the Sunshine Coast in Australia. Mar Drugs, 6, 243-261. (Pubitemid 351919082)
31. Fenical W. (2006). Marine pharmaceuticals: past, present, and future. Oceanography, 19, 110-119.
32. Fenical W, Jensen PR. (2006). Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol, 2, 666-673. (Pubitemid 44764208)
33. Fiedler HP, Bruntner C, Bull AT, Ward AC, Goodfellow M, Potterat O, Puder C, Mihm G. (2005). Marine actinomycetes as a source of novel secondary metabolites. Antonie van Leeuwenhoek, 87, 37-42. (Pubitemid 40331510)
34. Fleming JD, Nisbet LJ, Brewer SJ. (1982). Target Directed Antimicrobial Screens. In: Bu'lock JD, et al., ed. Bioactive Microbial Products: Search and Discovery. New York: Academic Press, 107-130.
35. Galatenko OA, Terekhova LP, Preobrazhenskaya TP. (1990). The Application of Ultraviolet Irradiations to the Isolation of Rare Actinomycete Genera. In: Poisk Produtsentov Antibiotikov Sredi Aktinomitsetov Redkikh Rodov (Search for Antibiotic Producers Among Rare Actinomycete Genera). Golym: Alma-Ata, 29-35.
36. Goldman MA. (2005). Digital drug discovery. Genome Biology, 6, 348-350.
37. Goodfellow M. (1983). Ecology of actinomycetes. Annu Rev Microbiol, 37, 189-216.
38. Goodfellow M. (2010). Selective Isolation of Actinobacteria. In: Baltz RH, Davies J, Demain AL, eds. Manual of Industrial Microbiology and Biotechnology. Section 1: Isolation and Screening of Secondary Metabolites and Enzymes, Bull AT, Davies JE (section eds). Washington: ASM Press, 3, 13-27.
39. Goodfellow M, Fiedler, H-P. (2010). A guide to successful bioprospecting: informed by actinobacterial systematics. Antonie van Leeuwenhoek, 98, 119-142.
40. Hamaki T, Suzuki M, Fudou R, Jojima Y, Kajiura T, Tabuchi A, Sen K, Shibai H. (2005). Isolation of novel bacteria and actinomycetes using soil-extract agar medium. J Biosci Bioeng, 99, 485-492. (Pubitemid 40874527)
41. Handelsman J. (2004). Soils-the Metagenomics Approach. In: Bull AT, ed. Microbial Diversity and Bioprospecting. Washington: ASM Press, 109-119.
42. Hayakawa M. (2008). Studies on the isolation and distribution of rare actinomycetes in soil. Actinomycetologica, 22, 12-19.
43. Hayakawa M, Nonomura H. (1987a). Efficacy of artificial humic acid as a selective nutrient in HV agar used for the isolation of soil actinomycetes. J Ferment Technol, 65, 609-616.
44. Hayakawa M, Nonomura H. (1987b). Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J Ferment Technol, 65, 501-509.
45. Hayakawa M, Tamura T, Nonomura H. (1991). Selective isolation of Actinoplanes and Dactylosporangium from soil by using gammacollidine as the chemoattractant. J Ferment Bioeng, 72, 426-432.
46. Hayakawa M, Kajiura T, Nonomura H. (1991a). New methods for the highly selective isolation of Streptosporangium and Dactylosporangium from soil. J Ferment Bioeng, 72, 327-333.
47. Hayakawa M, Sadakata T, Kajiura T, Nonomura H. (1991b). New methods for the highly selective isolation of Micromonospora and Microbispora from soil. J Ferment Bioeng, 72, 320-326.
48. Hayakawa M, Iino H, Takeuchi S, Yamazaki T. (1997). Application of a method incorporating treatment with Chloramine-T for the selective isolation of Streptosporangiaceae from soil. J Ferment Bioeng, 84, 599-602. (Pubitemid 128752702)
49. Hertzberg RP. (1993). Whole cell assays in screening for biologically active substances. Curr Opin Biotechnol, 4, 80-84. (Pubitemid 23073865)
50. Hill DC, Wrigley SK, Nisbet LJ. (1998). Novel screen methodologies for identification of new microbial metabolites with pharmacological activity. Adv Biochem Eng Biotechnol, 59, 75-121.
51. Holtzel A, Kemter C, Metzger JW, Jung G, Groth I, Fritz T, Fiedler H-P. (1998). Biosynthetic capacities of actinomycetes. 10. Spirofungin, a new antifungal antibiotic from Streptomyces violaceusniger TU 4113. J Antibiot, 51, 699-707. (Pubitemid 28432861)
52. Ishikawa J. (2008). Genome analysis system for actinomycetes: development and application. Actinomycetologica, 22(2), 46-49.
53. Iwai H, Takahashi Y. (1992). Selection of Microbial Sources of Bioactive Compounds. In: Omura S, ed. The Search for Bioactive Compounds from Microorganisms. New York: Springer-Verlag, 281-302.
54. Kim CJ, Lee KH, Shimazu A, Kwon OS, Park DJ. (1995). Isolation of rare actinomycetes in various types of soil. K J Appl Microbiol Biotechnol, 23, 36-42.
55. Kizuka M, Enokita R, Takahashi K, Okazaki T. (1997). Distribution of the actinomycetes in the Republic of South Africa investigated using a newly developed isolation method. Actinomycetologia, 11, 54-55.
56. Klabunde T. (2006). Chemogenomic approaches to ligand design. In: Rognan D, ed. Ligand design for G protein-coupled receptors. Weinheim: Wiley-VCH.
57. Klabunde T. (2007). Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol, 152, 5-7. (Pubitemid 47339899)
58. Lam KS. (2006). Discovery of novel metabolites from marine actinomycetes. Curr Opin Microbiol, 9, 245-251. (Pubitemid 43817620)
59. Lamari L, Zitouni A, Boudjella H, Badji B, Sabaou N, Lebrihi A, Lefebvre G, Seguin E, Tillequin F. (2002). New dithiolopyrrolone antibiotics from Saccharothrix sp. SA 233. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot, 55, 696-701. (Pubitemid 35012547)
60. Lancini G, Lorenzetti R. (1993). Biotechnology of Antibiotics and other Bioactive Microbial Metabolites. New York, London: Plenum Press, 49-57.
61. Lazzarini A, Cavaletti L, Toppo G, Marinelli F. (2001). Rare genera of actinomycetes as potential producers of new antibiotics. Antonie van Leeuwenhoek, 79, 399-405. (Pubitemid 33069335)
62. Lechevalier HA, Lechevalier MP. (1967). Biology of actinomycetes. Annu Rev Microbiol, 21, 71-100.
63. Li-Hua H, Qi-Ren L, Cheng-Lin J. (1996). Diversity of soil actinomycetes in Japan and China. Appl Environ Microbiol, 62, 244-248. (Pubitemid 26477065)
64. Li Yu. V, Terekhova LP, Gapochka MG. (2002a). Isolation of actinomycetes from soil using extremely high-frequency radiation. Mikrobiologiya, 71, 119-122. (Pubitemid 44784850)
65. Li Yu. V, Terekhova LP, Alferova IV, Gapochka MG. (2002b). The use of EHF radiation in different wavelength bands for the selective isolation of actinomycetes from soil. Biomed Radioelektron, 5, 20-24.
66. Long PF, Wildman HG, Amphlett GE. (1994). The use of statistical models to predict the effects of pretreatments on the total viable counts of actinomycetes isolated from soil. Actinomycetes, 5, 1-8.
67. Miquely E, Martin C, Hardisson C, Manzanal MB. (1993). Synchronous germination of Streptomyces antibioticus spores: tool for the analysis of hyphal growth in liquid. FEMS Microbiol Lett, 109, 123-300.
68. Mochalkin I, Miller JR, Narasimhan L, Thanabal V, Erdman P, Cox PB, Prasad JV, Lightle S, Huband MD, Stover CK. (2009). Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol, 4, 397-399.
69. Newman DJ, Cragg GM. (2007). Natural products as sources of new drugs over the last 25 years. J Nat Prod, 70, 461-477. (Pubitemid 46595760)
70. Nisbet LJ. (1982). Current strategies in the search for bioactive microbial metabolites. J Chem Technol Biotechnol, 32, 251-270.
71. Nolan RD, Cross T. (1988). Isolation and Screening of Actinomycetes. In: Goodfellow M, Williams ST, Mordarski M, eds. Actinomycetes in Biotechnology. London: Academic Press, 2-8.
72. Nonomura H. (1988). Isolation, taxonomy and ecology of soil actinomycetes. Actinomycetologia, 3, 45-54.
73. Okami B, Hotta AK. (1988). Search and Discovery of New Antibiotics. In: Goodfellow M, Williams ST, Mordarski M, ed. Actinomycetes in Biotechnology. Oxford: Pergamon Press, 33-67.
74. Okoro CK, Brown R, Jones AL, Andrews BA, Asenjo JA, Goodfellow M, Bull AT. (2009). Diversity of culturable actinomycetes in hyper-arid soils of the Atacama Desert, Chile. Antonie van Leeuwenhoek, 95, 121-133.
75. Omura S, Ikeda H, Ishikawa J, Hanamoto A, Takahashi C, Shinose M, Takahashi Y, Horikawa H, Nakazawa H, Osonoe T, Kikuchi H, Shiba T, Sakaki Y, Hattori M. (2001). Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc Natl Acad Sci USA, 98, 12215-12220. (Pubitemid 32959853)
76. O'Shea R, Moser HE. (2008). Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem, 51, 2871-8. (Pubitemid 351706014)
77. Palleroni NJ. (1980). A chemotactic method for the isolation of Actinoplanaceae. Arch Microbiol, 128, 53-55. (Pubitemid 11164955)
78. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov, 6, 29-40. (Pubitemid 46020284)
79. Perí-Concha Natasa, Long PF. 2003. Mining the microbial metabolome: a new frontier for natural product lead discovery. Drug Discov Today, 8, 1078-1084. (Pubitemid 38124473)
80. Pfefferle C, Theobald U, Gürtler H, Fiedler H-P. (2000). Improved secondary metabolite production in the genus Streptosporangium by optimization of the fermentation conditions. J Biotechnol, 80, 135-142. (Pubitemid 30450147)
81. Roda A, Guardigli M, Pasini P, Mirasoli M. (2003). Bioluminescence and chemiluminescence in drug screening. Anal Bioanal Chem, 377, 826-833. (Pubitemid 40877848)
82. Sabaou N, Boudjella H, Bennadji A, Mostefaoui A, Zitouni A, Lamari L, Bennadji H. (1998). Les sols des oasis du Sahara algérien, source d'actinomycètes rares producteurs d'antibiotiques. Sécheresse, 9, 147-153.
83. Scherlach K, Hertweck C. (2009). Triggering cryptic natural product biosynthesis in microorganisms. Org Biomol Chem, 7, 1753-1760.
84. Schloss PD, Handelsman J. (2005). Metagenomics for studying unculturable microorganisms: cutting the Gordian knot. Genome Biol, 6, 229-232.
85. Singh SB, Barrett JF. (2006). Empirical antibacterial drug discoveryfoundation in natural products. Biochem Pharmacol, 71, 1006-15.
86. Sogin ML, Morrison HG, Huber JA, Welch DM, Huse SM, Neal PR, Arrieta JM, Herndl GJ. (2006). Microbial diversity in the deep sea and the underexplored "rare biosphere". Proc Natl Acad Sci USA, 103, 12115-12120. (Pubitemid 44215820)
87. Sosio M, Bossi E, Bianchi A, Donadio S. (2000). Multiple peptide synthetase gene clusters in actinomycetes. Mol Gen Genet, 264, 213-221.
88. Stach JEM, Bull AT. (2005). Estimating and comparing the diversity of marine actinobacteria. Antonie Van Leeuwenhoek, 87, 3-9. (Pubitemid 40331506)
89. Steffan RJ, Goskøyr J, Bej AK, Atlas RM. (1988). Recovery of DNA from soil and sediments. Appl Environ Microbiol, 54, 2908-2915.
90. Tishkov S. (2001). Bioactive Products from Actinomycetes-antibiotics, Enzyme Inhibitors, Immunomodulators. In: Moncheva P, Tishkov S, Chipeva V, ed. Innovative Aspects in Biotechnology of Prokaryotes. Sofia: National bank for industrial microorganisms and cell cultures, 111-138.
91. Tomoda H, Omura S. (1990). New strategy for discovery of enzyme inhibitors: screening with intact mammalian cells or intact microorganisms having special functions. J Antibiot, 43, 1207-l223.
92. Umezawa H. (1982). Low molecular-weight enzyme inhibitors of microbial origin. Annu Rev Microbiol, 36, 75-99.
93. Walters WP, Namchuk M. (2003). Designing screens: how to make your hits a hit. Nat Rev Drug Discov, 2, 259-266. (Pubitemid 37361684)
94. Ward DM, Weller R, Bateson MM. (1990). 16S rRNA sequences reveal numerous uncultured microorganisms in a natural community. Nature, 345, 63-65.
95. Watve MG, Shejval V, Sonawane C, Rahalkar M, Matapurkar M, Shouche Y, Patole M, Phadnis N, Champhekar A, Damle K, Karandikar S, Kshirsagar V, Jog M. (2000). The 'K' selected oligophilic bacteria: a key to uncultured diversity? Curr Sci, 78, 1535-1542.
96. Watve G, Tickoo R, Jog MM, Bhole BD. (2001). How many antibiotics are produced by the genus Streptomyces? Arch Microbiol, 176, 391-392.
97. Weinbauer MG, Beckmann C, Hofle MG. (1998). Utility of green fluorescent nucleic acid dyes and aluminum oxide membrane filters for rapid epifluorescence enumeration of soil and sediment bacteria. Appl Environ Microbiol, 64, 5000-5003. (Pubitemid 28557872)
98. Wermuth CG. (2004). Selective optimization of side affinities: another way for drug discovery. J Med Chem, 47, 1303-1314. (Pubitemid 38327456)
99. Williams ST, Wellington EMH. (1982). Principles and problems of selective isolation of microbes. In: Bu'lock JD, Nisbet LJ, Winstanley DJ, ed. Bioactive microbial products: search and discovery. London: Academic Press, 9-26.
100. Zazopoulos E, Huang K, Staffa A, Liu W, Bachmann BO, Nonaka K, Ahlert J, Thorson JS, Shen B, Farnet CM. (2003). A genomicsguided approach for discovering and expressing cryptic metabolic pathways. Nat Biotechnol, 21, 187-190. (Pubitemid 36188219)
101. Zengler K, Walcher M, Clark G, Haller I, Toledo G, Holland T, Mathur EJ, Woodnutt G, Short JM, Keller M. (2005). High-throughput cultivation of microorganisms using microcapsules. Methods Enzymol, 397, 124-130. (Pubitemid 41562896)
102. Zinder SH. (2002). The future for culturing environmental organisms: a golden era ahead? Environ Microbiol, 4, 14-15.
103. Zitouni A, Boudjella H, Mathieu F, Sabaou N, Lebrihi A. (2004a). Mutactimycin PR, a new anthracycline antibiotic from Saccharothrix sp. SA 103. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot, 57, 367-372. (Pubitemid 38997476)
104. Zitouni A, Lamari L, Boudjella H, Badji B, Sabaou N, Gaouar A, Mathieu F, Lebrihi A, Labeda DP. (2004b). Saccharothrix algeriensis sp. nov., isolated from Saharan soil. Int J Syst Evol Microbiol, 54, 1377-1381. (Pubitemid 39139863)